Disappearance of anti-HLA antibodies in highly sensitized patients treated with erythropoietin.
Mourad
G
G
Department of Nephrology, Hôpital Lapeyronie, Montpellier, France.
Cristol
J P
JP
Chong
G
G
Lorho
R
R
Argiles
A
A
Seignalet
J
J
Mion
C
C
D000328:Adult; D000961:Antilymphocyte Serum / Q000032:analysis; D001803:Blood Transfusion; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006084:Graft Rejection / Q000276:immunology* / Q000628:therapy; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D007262:Infusions, Intravenous; D007518:Isoantibodies / Q000032:analysis*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000276:immunology* / Q000628:therapy; D006435:Renal Dialysis; D013601:T-Lymphocytes / Q000276:immunology; D014019:Tissue Donors
D000961:Antilymphocyte Serum; D006680:HLA Antigens; D007518:Isoantibodies; D004921:Erythropoietin